Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects
Phase of Trial: Phase III
Latest Information Update: 26 Jun 2019
Price : $35 *
At a glance
- Drugs Pancrelipase (Primary)
- Indications Exocrine pancreatic insufficiency; Pancreatitis
- Focus Therapeutic Use
- Acronyms CREON
- Sponsors Abbott Laboratories
- 24 Jun 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 24 Jun 2019 Planned primary completion date changed from 11 Feb 2019 to 11 Feb 2020.
- 07 Mar 2018 New trial record